Meeting
2021 ASCO Annual Meeting
Computational features of tumor-infiltrating lymphocyte architecture of residual disease after chemotherapy on H&E images as prognostic of overall and disease-free survival for triple-negative breast cancer.
Authors
Germán Corredor
Case Western Reserve University, Cleveland, OH
Germán Corredor , Paula Toro , Cheng Lu , Pingfu Fu , Shaveta Vinayak , Miluska Castillo Garcia , Luis A. Bernabe , Carlos Arturo Castaneda Altamirano , Alberto J. Montero , Aparna Harbhajanka , Hannah L. Gilmore , Anant Madabhushi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 584)
DOI
10.1200/JCO.2021.39.15_suppl.584
Abstract #
584
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).
First Author: Stephen James Luen
Poster
2021 Gastrointestinal Cancers Symposium
Disease-free and overall survival in nonmetastatic esophageal or gastroesophageal junctional cancer after treatment with curative intent: A nationwide population-based study.
First Author: Marieke Pape
Poster
2019 ASCO Annual Meeting
CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).
First Author: William M. Sikov
Poster
2017 ASCO Annual Meeting
Adjuvant or neoadjuvant chemotherapy in early stage triple negative breast cancer (TNBC) comparison of outcomes in both BRCA positive and BRCA negative patients.
First Author: Katherine Clifton